leisure time -WSS

leisure time

author：fashion 2025-09-30 18:48:09 - browse：217

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： FDA's naming rule on biosimilars has undermined competition

hotspot

leisure time

explore

WSS

Anavex keeps shifting the goalposts in its clinical trials

FDA panel issues narrow recommendation for Covid vaccine booster doses

FDA's naming rule on biosimilars has undermined competition

Scientists boost immune system in aging mice by making it youthful

Methadone doses haven’t kept up in the age of fentanyl

NIH trials fail to test meaningful long Covid therapies, experts say

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Hepatitis C has a cure — but many Americans still lack access to it

Primary care physicians play key roles in Alzheimer's management

Affirmative action in medical school literally saved lives

FDA's naming rule on biosimilars has undermined competition

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

For Cytokinetics, FDA rejection of heart drug would help, not hinder

How to save PrEP access — and even expand it

Food as medicine: Medically tailored meals may get standardized

Moonlake's readout produced a cash windfall. Risks remain

Why the world’s most expensive drug might be worth the price

hotspot

Oprah kicked off a national conversation on obesity. Let's have it

In same hospitals, Black patients receive fewer opioids than white patients

The best solution to the drug shortages problem

States should stop sabotaging methadone treatment reform

In same hospitals, Black patients receive fewer opioids than white patients

FDA's naming rule on biosimilars has undermined competition

hotspot

leisure time

explore

explore